Phil Palumbo, a senior equity strategist at a major investment bank, highlighted that Salesforce has “nothing broken” in its core business despite recent market volatility. He noted the company’s robust enterprise software suite, which serves over 150,000 customers globally, and praised its transition toward profitability. Palumbo pointed out that Salesforce’s free cash flow multiple has contracted to approximately 14× – well below its 10-year average – creating an attractive entry point. He reiterated a bullish stance based on management’s ability to sustain 10% revenue CAGR through fiscal 2030 and a $60 billion long-term revenue target driven by disciplined cost controls and high-margin cloud services.

Salesforce announced a strategic partnership with Viz.ai to integrate real-time clinical data from nearly 2,000 U.S. hospitals covering 230 million lives into its Agentforce Life Sciences platform. The new service will unify clinical triggers and customer engagement workflows, enabling pharmaceutical clients to orchestrate guideline-based next-best actions across sales, medical science liaison and patient support teams. To date, over 110 life science companies have adopted Agentforce Life Sciences; with the Viz.ai Data 360 connector, customers can now reduce patient onboarding drop-off by automating HUB referrals, benefits verification and prior-authorization support directly at point of care.

In its latest quarterly disclosure, Salesforce reported that annualized recurring revenue (ARR) for its AI-driven Agentforce product reached $540 million, a 330% increase compared to the prior year period. Remaining performance obligations (RPO) also grew 12% year-over-year, reflecting healthy backlog expansion across commercial and regulated-industries divisions. Management emphasized that accelerating adoption of agentic AI features is a key driver in narrowing the valuation gap to peers, even as the company maintains disciplined operating margins. Analysts project that Agentforce could contribute up to $3 billion in incremental revenue by fiscal 2028, supporting the case for a multiple re-rating toward historical averages.